What does PHARMACIE DE LA COUR do?

PHARMACIE DE LA COUR is a pharmacy in Brussel. Public Limited, started on 13 December 1989, 1 establishment.

What is the address of PHARMACIE DE LA COUR?

The registered office of PHARMACIE DE LA COUR is located at Naamsestraat 76, 1000 Brussel.

Is PHARMACIE DE LA COUR still active?

Yes. According to the CBE (29 September 2026) PHARMACIE DE LA COUR is active, legal situation “Normale toestand”, started on 13 December 1989.

Is PHARMACIE DE LA COUR registered on Peppol?

Yes, PHARMACIE DE LA COUR is registered on the Peppol network with ID 0208:0439367933.

What is the enterprise number of PHARMACIE DE LA COUR?

The enterprise number of PHARMACIE DE LA COUR is BE0439367933.

When was PHARMACIE DE LA COUR founded?

PHARMACIE DE LA COUR was founded on 13 December 1989.

Who owns PHARMACIE DE LA COUR?

The shares are held by PHARMAMULTISERVICES.

Is PHARMACIE DE LA COUR a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 13 December 1989; 4 annual accounts filed, latest fiscal year 2024.

How much profit did PHARMACIE DE LA COUR make in 2024?

PHARMACIE DE LA COUR posted a profit after taxes of € 19,710 in financial year 2024.

What is the revenue of PHARMACIE DE LA COUR?

As a small company, PHARMACIE DE LA COUR is not required to publish revenue in its annual accounts. In financial year 2024, its added value was € 103,310.

PHARMACIE DE LA COUR (Public Limited) - Brussel

Dossier PHARMACIE DE LA COUR, printed on 29 September 2026 from databakkes.be/en/0439367933/pharmacie-de-la-cour. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Tight liquidity NBB

Cash and receivables cover 60 % of short-term debt in 2024; threshold 65 %.

Financials

Financial year 2024

PHARMACIE DE LA COUR from Brussel, company number BE0439367933, closed financial year 2024 with a result of € 19,710 after tax. For that financial year PHARMACIE DE LA COUR recorded a gross margin of € 103,310 and equity of € 330,437. Compared with financial year 2023, the result moved from € 68,422 to € 19,710. The company is profitable. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on October 29, 2025.

What it is worth Growing

€ 330,437

▲ 1% vs 2023

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 19,710

▼ 71% vs 2023

Profit after tax over the fiscal year.

Cash in the bank

€ 15,202

▲ € 15,167 vs 2023

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 15,000 paid out

76 % of the profit went to the shareholders, the rest stayed in the company.

People and assets in 2024

Vehicles and equipment

€ 3,618

▼ 45% vs 2023

Book value of vehicles, furniture and equipment.

Debts at end 2024

Bank debt ≈ 18 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 351,571

▼ 3% vs 2023

€ 17,951 is repaid this year. At this pace the long-term loan is gone in ≈ 18 years.

Owed to suppliers

€ 282,197

▲ 58% vs 2023

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 5,535

▲ 121% vs 2023

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2021	2022	2023	2024	Change 2023 → 2024
Gross margin	€ 210,458 Gross margin 2021: € 210,458 First fiscal year in the series	€ 184,749 Gross margin 2022: € 184,749 ▼ 12% vs 2021 (€ 210,458) Unfavourable step	€ 129,783 Gross margin 2023: € 129,783 ▼ 30% vs 2022 (€ 184,749) Unfavourable step	€ 103,310 Gross margin 2024: € 103,310 ▼ 20% vs 2023 (€ 129,783) Unfavourable step	▼ 20%
Profit after taxes	€ 122,781 Profit after taxes 2021: € 122,781 First fiscal year in the series	€ 115,685 Profit after taxes 2022: € 115,685 ▼ 6% vs 2021 (€ 122,781) Unfavourable step	€ 68,422 Profit after taxes 2023: € 68,422 ▼ 41% vs 2022 (€ 115,685) Unfavourable step	€ 19,710 Profit after taxes 2024: € 19,710 ▼ 71% vs 2023 (€ 68,422) Unfavourable step	▼ 71%
Equity	€ 330,620 Equity 2021: € 330,620 First fiscal year in the series	€ 329,305 Equity 2022: € 329,305 Unchanged (€ 330,620) Unfavourable step	€ 325,727 Equity 2023: € 325,727 ▼ 1% vs 2022 (€ 329,305) Unfavourable step	€ 330,437 Equity 2024: € 330,437 ▲ 1% vs 2023 (€ 325,727) Favourable step	▲ 1%
Total debts	€ 868,024 Total debts 2021: € 868,024 First fiscal year in the series	€ 871,093 Total debts 2022: € 871,093 Unchanged (€ 868,024) Unfavourable step	€ 735,672 Total debts 2023: € 735,672 ▼ 16% vs 2022 (€ 871,093) Favourable step	€ 654,303 Total debts 2024: € 654,303 ▼ 11% vs 2023 (€ 735,672) Favourable step	▼ 11%
Cash	€ 447 Cash 2021: € 447 First fiscal year in the series	-	€ 35 Cash 2023: € 35 First fiscal year in the series	€ 15,202 Cash 2024: € 15,202 ▲ € 15,167 vs 2023 (€ 35) Favourable step	▲ € 15,167
Land & buildings	€ 628,230 Land & buildings 2021: € 628,230 First fiscal year in the series	€ 611,053 Land & buildings 2022: € 611,053 ▼ 3% vs 2021 (€ 628,230) Unchanged	€ 593,875 Land & buildings 2023: € 593,875 ▼ 3% vs 2022 (€ 611,053) Unchanged	€ 576,698 Land & buildings 2024: € 576,698 ▼ 3% vs 2023 (€ 593,875) Unchanged	▼ 3%
Retained profit	€ 268,620 Retained profit 2021: € 268,620 First fiscal year in the series	€ 267,305 Retained profit 2022: € 267,305 Unchanged (€ 268,620) Unfavourable step	€ 263,727 Retained profit 2023: € 263,727 ▼ 1% vs 2022 (€ 267,305) Unfavourable step	€ 268,437 Retained profit 2024: € 268,437 ▲ 2% vs 2023 (€ 263,727) Favourable step	▲ 2%
Dividend	€ 120,000 Dividend 2021: € 120,000 First fiscal year in the series	€ 117,000 Dividend 2022: € 117,000 ▼ 2% vs 2021 (€ 120,000) Unchanged	€ 72,000 Dividend 2023: € 72,000 ▼ 38% vs 2022 (€ 117,000) Unchanged	€ 15,000 Dividend 2024: € 15,000 ▼ 79% vs 2023 (€ 72,000) Unchanged	▼ 79%
Bank debt	€ 395,438 Bank debt 2021: € 395,438 First fiscal year in the series	€ 378,949 Bank debt 2022: € 378,949 ▼ 4% vs 2021 (€ 395,438) Favourable step	€ 363,761 Bank debt 2023: € 363,761 ▼ 4% vs 2022 (€ 378,949) Favourable step	€ 351,571 Bank debt 2024: € 351,571 ▼ 3% vs 2023 (€ 363,761) Favourable step	▼ 3%
Balance sheet total	€ 1,244,543 Balance sheet total 2021: € 1,244,543 First fiscal year in the series	€ 1,244,833 Balance sheet total 2022: € 1,244,833 Unchanged (€ 1,244,543) Unchanged	€ 1,104,369 Balance sheet total 2023: € 1,104,369 ▼ 11% vs 2022 (€ 1,244,833) Unchanged	€ 1,026,244 Balance sheet total 2024: € 1,026,244 ▼ 7% vs 2023 (€ 1,104,369) Unchanged	▼ 7%

Key figures of PHARMACIE DE LA COUR, fiscal years 2021 to 2024, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2025 has not been filed yet; it was expected before 31 July 2026.

What happened to PHARMACIE DE LA COUR?

What happened at PHARMACIE DE LA COUR in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Oct 29, 2025 New annual accounts for financial year 2024: profit of € 19,710 (▼ 71% vs 2023). filed late Source: NBB ↗
Jan 16, 1990 New establishment in Brussel. KBO
Dec 13, 1989 Start of the company according to the CBE. KBO

In short

From € 122,781 profit in 2021 to € 19,710 profit in 2024.

Paid € 9,137 in corporate taxes since 2021.

Best year ever: 2021, with € 122,781 profit.

Paid out € 324,000 in dividends to the owners in total.

Original PDFs at the National Bank ↗

A new publication or filing at PHARMACIE DE LA COUR? We notify you, reason included.

Follow PHARMACIE DE LA COUR

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Establishments

Establishment units

Physical locations of this company

Registered office

Naamsestraat 76

1000 Brussel

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 3 companies are registered at this address.

All companies at this address →

BELGIAN FOOD TRADING

€ -1,742 gross margin · 2025

K.H. SKIN

€ -13,774 gross margin · 2024

PHARMA MULTISERVICES same network

€ 58,096 gross margin · 2024

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0439.367.933

VAT number

BE 0439.367.933

Registered office

Naamsestraat 76, 1000 Brussel

Names & denominations

PHARMACIE DE LA COUR

Enterprise type

Rechtspersoon

Legal form

Public limited company

Legal situation

Normale toestand

Start date

13 December 1989

Peppol

Active · Active since 19 Dec 2025

Activities · NACE

Detailhandel in farmaceutische producten

Apothekers

View on CBE Public ↗ Annual accounts (NBB) ↗